

i2O Therapeutics Announces Research Collaboration with Sanofi to Enable Oral Delivery of Nanobody-Based Medicines

Partnership to create new treatment delivery options for people facing serious diseases

BOSTON, MA—February 10, 2021—[i2O Therapeutics](#), developers of a platform for oral delivery of traditionally injectable biological drugs, announced today a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody[®]-based medicines, which are currently administered through intravenous or subcutaneous injections.

Nanobodies - proprietary therapeutic proteins based on camelid derived immunoglobulin single variable domains - have potential uses in the treatment of a range of serious and life-threatening diseases and are being developed in many therapeutic areas including inflammation, hematology, immuno-oncology, oncology and rare diseases. The research collaboration between i2O Therapeutics and Sanofi will explore a new oral route of administering nanobodies.

“Our mission at i2O Therapeutics is to develop safe and effective oral formulations of therapies traditionally limited to injections and we are excited to partner with Sanofi to advance this mission,” said Ravi Srinivasan, co-founder and director of i2O Therapeutics.

“i2O’s ionic liquid platform opens new opportunities to orally deliver biologics, and nanobodies represent an exciting application of this platform,” said Samir Mitragotri, co-founder of i2O Therapeutics.

i2O Therapeutics [announced](#) seed funding in April 2020, which was led by Sanofi Ventures, the corporate venture capital arm of Sanofi, and JDRF T1D Fund. The company also [announced](#) a strategic investment from Colorcon Ventures, the corporate venture capital fund of Colorcon, Inc. in December 2020.

About i2O Therapeutics

i2O Therapeutics is a biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, this platform leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2O is focused on creating the next generation of oral peptide and protein-based therapies. Visit us at www.i2OBio.com.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Contact

Lauren Arnold

MacDougall

larnold@macbiocom.com

781-235-3060